Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06297772 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 4, 2024 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Apr 1, 2024 to Jun 1, 2024v4
  2. Start date: Mar 1, 2024 to Apr 1, 2024v3
  3. Study description expanded, about 1 word Study title shortened, about 1 wordv2 Show 1 more changeShow less
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as pretreatment regimens for the treatment of acute myeloid leukemia in adults with MR gene abnormalities
Trial Details
NCT Number NCT06297772
Lead Sponsor Ruijin Hospital
Conditions AML, Adult
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov